Welcome to our dedicated page for Autonomix Medical SEC filings (Ticker: AMIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Autonomix Medical, Inc. (NASDAQ: AMIX) SEC filings page on Stock Titan brings together the company’s registration statements, current reports, and other disclosures filed with the U.S. Securities and Exchange Commission. Autonomix is a development-stage medical device company focused on catheter-based nerve-sensing and targeted ablation technologies for conditions such as pancreatic cancer pain and potential cardiology and chronic disease applications.
Through this page, readers can access registration statements on Form S-1 and S-1/A, which describe Autonomix’s business, risk factors, capital structure, and details of securities offerings. These filings include information on the company’s status as a smaller reporting company and emerging growth company, its incorporation in Delaware, and its listing of common stock on Nasdaq under the symbol AMIX. They also provide context on warrants, stock plans, license agreements, and other material contracts referenced in the exhibits.
Investors can also review current reports on Form 8-K that Autonomix files to report material events. Examples include securities purchase agreements for private placements of common stock and warrants, at-the-market issuance sales agreements with investment banks, and a purchase agreement with an institutional investor committing to buy shares of common stock over time, subject to conditions. These 8-K filings outline terms such as exercise prices, beneficial ownership limits, use of proceeds for working capital and general corporate purposes, and restrictions on additional equity transactions.
Stock Titan’s platform adds AI-powered summaries that help explain the key points in lengthy filings, such as how warrant structures work, what an at-the-market agreement allows, or how a purchase agreement with an institutional investor may affect potential dilution. Users can quickly identify where Autonomix discusses its development-stage medical device business, nerve-sensing and ablation platform, equity financing arrangements, and governance matters, without reading every line of the underlying documents.
In addition to S-1 and 8-K filings, this page links to other SEC documents referenced by Autonomix, such as shelf registration statements, stock plans, and license agreements. For those tracking AMIX, the filings page offers real-time access to new submissions from EDGAR, along with structured views of items like unregistered sales of equity securities, at-the-market program changes, and material definitive agreements.
Autonomix Medical, Inc. reported another quarter as a pre-revenue, clinical-stage medical device company, advancing a catheter-based platform that combines nerve signal sensing with RF ablation to treat peripheral nervous system disorders, initially focused on pancreatic cancer pain and other visceral cancers.
For the nine months ended December 31, 2025, the company recorded a net loss of $14.0 million, up from $8.2 million a year earlier, driven by higher research and development spending of $5.7 million and general and administrative costs of $8.6 million. Cash used in operating activities was $9.4 million, leaving cash of $9.9 million and working capital of $8.5 million at period end.
Autonomix strengthened its balance sheet through equity financing, including at-the-market issuances, a Lincoln Park equity line, warrant inducement transactions and a November 2025 private placement that generated about $5.0 million in gross proceeds. However, the company had an accumulated deficit of $64.4 million and disclosed substantial doubt about its ability to continue as a going concern, estimating its current cash will fund operations into but not beyond the third calendar quarter of 2026 and that approximately $30–$36 million of additional financing will be needed to reach commercialization of its first indication.
Autonomix Medical, Inc. received a notice from Nasdaq that its common stock has failed to meet the minimum $1.00 per share bid price requirement for the last 30 consecutive business days, triggering a deficiency under Nasdaq’s continued listing rules.
The company has an initial 180-day grace period until July 13, 2026 to regain compliance by having its closing bid price at or above $1.00 for at least 10 consecutive business days. If it still falls short, Autonomix may qualify for a second 180-day period if it meets other Nasdaq Capital Market listing standards.
If compliance is not restored and no additional period is granted, Autonomix’s common stock may be delisted from Nasdaq, although the company could appeal. Management is monitoring the share price and may consider options such as a reverse stock split, but there is no assurance it will regain compliance.
Autonomix Medical, Inc. furnished an update highlighting new subgroup clinical data from its proof-of-concept study in pancreatic cancer-related pain. The analysis, presented at the 2026 ASCO Gastrointestinal Cancers Symposium, is described as demonstrating rapid, durable and meaningful pain relief in pancreatic cancer patients across all disease stages, expanding on previously reported results from the ongoing evaluation.
The company also posted an updated corporate presentation on its website, which is included as an exhibit. Both the press release and the investor presentation are furnished under a Regulation FD disclosure and are not deemed filed under federal securities laws unless later specifically incorporated by reference.
Autonomix Medical, Inc. has filed a prospectus covering the resale of up to 13,504,998 shares of common stock issuable upon exercise of outstanding warrants issued in a November 2025 PIPE transaction. This includes 9,003,332 shares underlying Series C common stock purchase warrants and 4,501,666 shares underlying pre-funded warrants. The company will not receive any proceeds from share resales by the selling stockholder but could receive up to $7.7 million in gross proceeds if all Common Warrants are exercised in cash, which it plans to use for working capital and general corporate purposes.
The warrants are immediately exercisable, with Common Warrants priced at $0.8607 per share and expiring five and a half years after issuance, and Pre-Funded Warrants priced at $0.001 per share and expiring when fully exercised. Shares outstanding were 6,907,678 as of November 21, 2025. The filing highlights that registering a large number of resale shares could pressure the stock price and materially dilute existing holders, and notes an auditor going concern paragraph regarding the company’s ability to continue as a going concern.
Autonomix Medical, Inc. is registering 13,504,998 shares of common stock for resale by a selling stockholder, issuable upon exercise of outstanding warrants from a November 2025 PIPE transaction. The shares consist of 9,003,332 shares underlying Series C common stock purchase warrants and 4,501,666 shares underlying pre-funded warrants.
The company will not receive any proceeds from the resale, but could receive up to $7.7 million in gross proceeds if all Common Warrants are exercised in cash at $0.8607 per share. The PIPE itself generated approximately $5.0 million in gross proceeds. Autonomix is a development-stage medical device company developing a catheter-based system that both senses neural signals and applies radiofrequency ablation, initially targeting severe pain from pancreatic and other visceral cancers.
As of November 21, 2025, Autonomix had 6,907,678 shares of common stock outstanding, so full warrant exercise would significantly increase the share count. Beneficial ownership caps of 4.99% for Common Warrants and 9.99% for Pre-Funded Warrants limit how many shares the investor can hold at any one time.
Autonomix Medical, Inc. entered into a Securities Purchase Agreement with an institutional investor for a private placement of pre-funded and Series C common stock warrants, raising gross proceeds of approximately $5.0 million before fees. The investor purchased pre-funded warrants for 4,501,666 shares at a combined price of $1.1097 per pre-funded warrant plus accompanying Series C common warrants, with the pre-funded warrants exercisable at $0.001 per share and the common warrants exercisable at $0.8607 per share for up to 9,003,332 shares. The company plans to use the net proceeds for working capital and general corporate purposes, has agreed to register the resale of the warrant shares, and is subject to agreed limits on additional equity and variable-rate transactions for a period tied to the effectiveness of that registration statement.
Autonomix Medical (AMIX) reported Q2 FY2026 results highlighting higher operating spend and ongoing losses. The company posted a net loss of $7.5 million for the quarter and $10.8 million for the six months ended September 30, 2025, driven by general and administrative expenses of $5.2 million and R&D of $2.4 million in the quarter. Cash and cash equivalents were $7.5 million at quarter end.
Management disclosed substantial doubt about the company’s ability to continue as a going concern. Based on current plans, cash resources are estimated to fund operations into, but not beyond, the third calendar quarter of 2026.
To bolster liquidity, Autonomix entered a $15.0 million equity purchase agreement with Lincoln Park and issued 261,932 commitment shares; no sales had occurred under this facility by September 30. The company also utilized its ATM program, selling 1,682,685 shares for approximately $2.6 million fiscal‑to‑date, including 378,425 shares for about $0.5 million in the quarter, and completed a July warrant inducement for roughly $2.5 million gross. Shares outstanding were 6,886,648 as of November 4, 2025.
Autonomix Medical (AMIX) reported stockholder voting results from its Annual Meeting. A total of 2,871,639 shares voted, representing approximately 48% of the 5,941,992 shares outstanding as of September 8, 2025, establishing a quorum. All five director nominees were elected. Stockholders ratified Forvis Mazars, LLP as independent auditor with 2,609,156 votes for, 91,309 against, and 171,174 abstentions.
Key approvals included capital flexibility items. Stockholders authorized the Board to implement a reverse stock split at a ratio between 1-for-2 and 1-for-25 prior to the one-year anniversary of the meeting (1,927,998 for; 370,030 against; 573,611 abstain). They approved the amended and restated 2023 Equity Incentive Plan (1,113,523 for; 127,874 against; 38,301 abstain) and, for Nasdaq Listing Rule 5635(d) purposes, authorized issuing more than 20% of outstanding common stock under the Lincoln Park Capital Fund, LLC purchase agreement (1,184,885 for; 75,982 against; 18,831 abstain).
Autonomix Medical, Inc. is a pre-revenue, clinical‑stage life sciences company developing peripheral nervous system sensing and treatment technologies. The filing shows no revenue for the reported periods and an accumulated deficit of approximately $50.4 million (year end) rising to $53.7 million as of June 30, 2025. Management reports working capital near $7.0–$7.9 million and cash of $8.6 million as of June 30, 2025, and discloses substantial doubt about the company's ability to continue as a going concern within one year. The company completed an equity offering that generated aggregate gross proceeds of about $10.0 million (net cash proceeds ~$9.0 million) in November 2024 and, under an ATM program, sold 1,304,260 shares for net proceeds of approximately $2.1 million through June 30, 2025. The filing details extensive warrant and unit arrangements (Series A, Pre‑Funded, Representative, Inducement and other warrants), convertible note conversions, stock option grants, and significant potential dilution from outstanding warrants and convertible instruments.
Autonomix Medical, Inc. filed Amendment No. 1 to its Form S-1 registration statement as an exhibits-only update. The amendment leaves the substantive disclosure in the original registration statement unchanged and adds or updates exhibits, including organizational documents, warrant forms, key employment and license agreements, underwriting and sales agreements, and XBRL-related materials.
The filing is signed on behalf of Autonomix Medical by Chief Executive Officer and President Brad Hauser and other senior officers and directors, confirming their authorization of this amended registration statement under the Securities Act of 1933.